β-Blockers in 1st Trimester Do Not Up Congenital Malformations
MONDAY, Oct. 15, 2018 -- Maternal use of β-blockers in the first trimester of pregnancy is not associated with a large increase in the risk for overall or cardiac congenital malformations, according to a study published online Oct. 16 in the Annals of Internal Medicine.
Brian T. Bateman, M.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues estimated the risks for major congenital malformations associated with first-trimester exposure to β-blockers using data from health registries in the five Nordic countries and the U.S. Medicaid database.
The researchers found that the β-blocker-associated pooled adjusted relative risk (RR) and risk difference per 1,000 persons exposed (RD1000) were 1.07 (95 percent confidence interval, 0.89 to 1.3) and 3 (confidence interval, −6.6 to 12.6) for any major malformation; 1.12 (95 percent confidence interval, 0.83 to 1.51) and 2.1 (confidence interval, −4.3 to 8.4) for any cardiac malformation; and 1.97 (95 percent confidence interval, 0.74 to 5.25) and 1 (confidence interval, −0.9 to 3) for cleft lip or palate. Based on the U.S. cohort data only, the adjusted RR and RD1000 were 1.37 (95 percent confidence interval, 0.58 to 3.25) and 1 (confidence interval, −2 to 4) for central nervous system malformations.
"The potential risks to the fetus must be balanced against the risks to the mother associated with untreated hypertension," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: October 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.